Develops ready-to-use, engineered immune-cell candidates from healthy donors for patients with cancer or autoimmune diseases.
10-K for FY2025, filed Mar 12, 2026
Allogene works through collaboration and license agreements with partners such as Servier; agreements can cover licenses, research and development, clinical manufacturing, and product supply.
10-K for FY2025, filed Mar 12, 2026
10-Q for Q3 FY2026, filed Nov 6, 2026
−$50.4MView ↗
8-K, filed Sep 2, 2026
On August 31, 2026, Geoffrey Parker, the Executive Vice President and Chief Financial Officer and principal financial officer of Allogene…View ↗
8-K, filed May 28, 2026
On May 28, 2026, the Board of Directors (the “Board”) of Allogene Therapeutics, Inc. (the “Company”), upon the recommendation of its…View ↗
8-K, filed May 13, 2026
Pursuant to the Termination Agreement, the parties agreed to terminate that certain Exclusive License Agreement, dated December 14, 2020…View ↗
Expanded into autoimmune disease
The older report describes a cancer-focused pipeline, while the latest report also develops engineered cell candidates for autoimmune diseases.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Mar 12, 2026We are a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates…View ↗
We are a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates…View ↗
Competes with AstraZeneca, Atara Biotherapeutics, Beam Therapeutics, Caribou Biosciences, CRISPR Therapeutics, Editas Medicine, Fate Therapeutics, Gilead Sciences, Imugene, Intellia Therapeutics, Legend Biotech, Precision Biosciences, Sana Biotechnology, Novartis, Bristol-Myers Squibb, and Autolus Therapeutics
10-K for FY2025, filed Mar 12, 2026Allogeneic T cell products have yet to receive FDA approval though the number of companies developing allogeneic product candidates is…View ↗
Loading...